Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Phase 1b Dose De-escalation Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2016 by University of California, San Francisco
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Jo Chien, University of California, San Francisco
ClinicalTrials.gov Identifier:
NCT01676753
First received: August 24, 2012
Last updated: March 15, 2017
Last verified: October 2016
  Purpose
The purpose of this trial is to determine the safety and tolerability (maximum tolerated dose (MTD)) of weekly dinaciclib in combination with every 3 week pembrolizumab in patients with advanced breast cancer. Once this is defined, a 20 patient dose expansion will be performed at this MTD in patients with metastatic or locally advanced and unresectable triple negative breast cancer, to evaluate the efficacy of combined dinaciclib and pembrolizumab.

Condition Intervention Phase
Advanced or Metastatic Breast Cancer
Triple Negative Breast Cancer
Drug: Dinaciclib & pembrolizumab treatment
Phase 1
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: A Phase 1b Dose De-escalation Trial of the Cyclin-dependent Kinase Inhibitor Dinaciclib in Combination With Pembrolizumab in Patients With Advanced Breast Cancer and Assessment of MYC Oncogene Overexpression

Resource links provided by NLM:


Further study details as provided by University of California, San Francisco:

Primary Outcome Measures:
  • Maximum tolerated dose (MTD) [ Time Frame: Measured during each Cycle (21 Days), with number of cycles dependent on number of adverse events (AE). MTD is defined as the dose at which no more than 1/6 patients experience a DLT (dose-limiting toxicity). ]
    The MTD is measured (safety/tolerability) by clinical review of relevant AE parameters (i.e. laboratory tests, physical exams)

  • Define dose-limiting toxicities (DLTs) [ Time Frame: Measured during each Cycle (21 Days), with number of cycles dependent on number of adverse events (AE) ]
    Toxicities will be graded in severity per CTCAE version 4.0, based on events occurring during the first Cycle for each cohort


Secondary Outcome Measures:
  • Anti-tumor activity in patients with advanced triple negative breast cancer [ Time Frame: Assessed every 9 weeks, from date of screening assessment (within 4 weeks of enrollment) until the date of ceased treatment (whether due to disease progression, death, adverse events or withdrawal), for the period of the study (estimated 2-3 years) ]
    Response and progression will be evaluated by diagnostic anatomic imaging and clinical exam. Overall tumor response and time to progression will be assessed using RECIST (Response Evaluation Criteria in Solid Tumors) 1.1 criteria and immune-related RECIST (irRECIST)

  • Biomarkers of dinaciclib and pembrolizumab activity [ Time Frame: Baseline (pre-treatment, within 4 weeks of Cycle 1 Day 1) ]
    Fresh tumor biopsies and RNA profiling of archived tissue will be assessed at baseline/pre-treatment, to correlate the biomarkers relevant to dinaciclib and pembrolizumab activity and MYC expression with clinical response. Optional in dose-finding phase, and if applicable in expansion phase


Estimated Enrollment: 32
Study Start Date: June 2016
Estimated Study Completion Date: August 2018
Estimated Primary Completion Date: June 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Dinaciclib & pembrolizumab treatment
Weekly dinaciclib in combination with every 3 week pembrolizumab
Drug: Dinaciclib & pembrolizumab treatment
Weekly dinaciclib in combination with every 3 week pembrolizumab
Other Name: Single Arm

Detailed Description:

This is an open-label phase Ib trial of weekly dinaciclib in combination with every 3 week pembrolizumab in patients with advanced breast cancer. Any number of prior therapies is allowed. Pembrolizumab will be administered every 3 weeks at a fixed dose of 200 mg IV. Dinaciclib will be administered D1 and D8 of a 21 day cycle by 2-hour intravenous infusion. In phase 1, the maximum tolerated dose (MTD) of dinaciclib monotherapy in solid tumors is 12 mg/m2. The starting dose level of this study will be dinaciclib 12 mg/m2 in combination with pembrolizumab 200 mg IV as no overlapping toxicities are expected. The dose-limiting toxicity (DLT) window is 21 days (1 cycle). The dose of dinaciclib will not be escalated beyond the 12 mg/m2 starting dose level, but dose de-escalation will occur if necessary following a 3+3 design.

The primary objective is to define the maximum tolerated dose of dinaciclib when given weekly in this combination and schedule. The primary endpoint is safety and tolerability. Once a MTD for dinaciclib is defined, a 20 patient dose expansion will be performed at the MTD in patients with metastatic or locally advanced and unresectable triple negative breast cancer. Secondary objectives include evaluation of the preliminary efficacy of this combination using RECIST 1.1 and irRECIST. Exploratory studies characterizing and correlating PDL-1 (programmed death ligand-1) and MYC (myelocytomatosis oncogene) overexpression with clinical response will be performed.

Tumor biopsies are optional in the dose escalation cohort, but mandatory in the dose expansion cohort unless otherwise specified.

  Eligibility

Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

INCLUSION CRITERIA:

Dose escalation phase

  1. Histologically or cytologically documented, incurable, unresectable locally advanced, or metastatic breast cancer
  2. The tumor biopsy is optional in the dose-finding phase of the protocol
  3. Patient is male or female and ≥18 years of age on the day of signing informed consent.
  4. Patient must have performance status of 0-2 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale and life expectancy > 3 months
  5. Patient must have evaluable disease
  6. Patient must have adequate organ function as indicated by the following laboratory values:

    Hematological

    • Absolute neutrophil count (ANC) ≥ 1,500 /μL
    • Platelets ≥ 100,000 /μL
    • Hemoglobin ≥ 9 g/dL

    Renal

    • Serum creatinine or calculated creatinine clearance ≤ 1.5 x upper limit of normal (ULN) OR
    • ≥ 60 mL/min for patients with creatinine levels > 1.5 x institutional ULN

    Hepatic

    • Serum total bilirubin ≤ 1.5 x ULN OR direct bilirubin ≤ ULN for patients with total bilirubin levels > 1.5 x ULN
    • Aspartate aminotransferase (AST) (SGOT) and alanine aminotransferase ALT (SGPT) ≤ 2.5 x ULN, ≤ 5 x ULN if liver metastasis

    Coagulation

    • Prothrombin time (PT)/International Normalized Ratio (INR) ≤ 1.2 x ULN
    • Partial thromboplastin time (PTT) ≤ 1.2 x ULN
  7. Female patient of childbearing potential must have a negative serum or urine pregnancy test β-hCG (human chorionic gonadotropin) within 72 hours prior to first doses of study medication . If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
  8. Female subjects of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study medication. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.
  9. Male subjects of childbearing potential must agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.
  10. Patient has voluntarily agreed to participate by giving written informed consent
  11. Any number of prior lines of chemotherapy in the metastatic setting is allowed
  12. Concomitant use of bisphosphonates or RANK-ligand (Receptor Activator of Nuclear factor Kappa-B ligand) inhibitors is allowed

Dose expansion phase

  1. Histologically documented metastatic or locally advanced unresectable breast cancer that is Estrogen Receptor (ER) and Progesterone Receptor (PR) <10% expression and does not over-express HER2 (human epidermal growth factor receptor 2) protein (IHC 0, 1+, or 2+and FISH (fluorescent in situ hybridization) <2.0)
  2. Patient must consent to a biopsy of a site of disease unless the only site of disease is lung/pleura, bone, or deemed unsafe by the principal investigator
  3. Patient must have measureable disease
  4. All other inclusion criteria per the dose escalation cohorts

EXCLUSION CRITERIA:

Both dose escalation and dose expansion cohorts

  1. Patient who has had radiotherapy or hormonal therapy within 2 weeks, chemotherapy within 3 weeks or 5 half-lives, whichever is shorter (6 weeks for nitrosoureas, mitomycin C or bevacizumab), anti-cancer monoclonal antibody for direct anti-neoplastic treatment within 4 weeks, or who has not recovered from toxicity due to previous agents administered. If the patient has residual toxicity from prior treatment, toxicity must be ≤ Grade 1 (except for neuropathy and alopecia).
  2. Patients less than 4 weeks post major surgical procedure (all surgical wounds must be fully healed). For the purpose of this criterion, a major surgical procedure is defined as one requiring the administration of general anesthesia.
  3. Patient is currently participating in a study with an investigational compound or device.
  4. Patient has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. However, patients with CNS metastases who have completed a course of therapy would be eligible for the study provided they are clinically stable for at least 4 weeks prior to entry as defined as: (1) no evidence of new or enlarging CNS metastasis on brain imaging within 4 weeks of enrollment (2) off steroids for 2 weeks. Patients with clinically insignificant brain metastases that do not require treatment are eligible.
  5. Patient has a primary central nervous system tumor
  6. Patient has known hypersensitivity to the components of study drug or its analogs.
  7. Patient has a history or current evidence of clinically significant heart disease including:

    • Clinically significant congestive heart failure, unstable angina pectoris,
    • Clinically significant cardiac arrhythmia,
    • Myocardial infarction during the last 6 months, and/or a current ECG tracing that is abnormal in the opinion of the treating Investigator,
    • QTc (corrected QT interval) prolongation >480 msec (Bazett's Formula),
    • Congenitally long QT syndrome, and/or current anti-arrhythmic therapy, a n d / o r has received any marketed or experimental compound in the last 1 week prior to entering the study with known effects of QT prolongation (Refer to The Arizona Center for Education and Research on Therapeutics (AZCERT) website),
  8. Patient with evidence of clinically significant bradycardia (HR <50), or a history of clinically significant bradyarrhythmias such as sick sinus syndrome, 2nd degree atrioventricular (AV) block (Mobitz Type 2), Patient with uncontrolled hypertension (≥140/90 mmHg). Patients who are controlled on antihypertensive medication will be allowed to enter the study.
  9. Patient has a history or current evidence of any condition, therapy, or lab abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate, in the opinion of the treating investigator.
  10. Patient has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
  11. Patient is, at the time of signing informed consent, a regular user of any illicit drugs or had a recent history (within the last year) of drug or alcohol abuse.
  12. Patient is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study
  13. Patient is known to be Human Immunodeficiency Virus (HIV)-positive
  14. Patient has known history of active Hepatitis A, B, or C
  15. Patients who have known allergic reactions to IV contrast dye despite standard prophylaxis
  16. Patients who require medications that are strong CYP3A4 inhibitors or inducers.
  17. Patients who have discontinued any of these medications must have a wash-out period of at least 5 days or at least 5 half-lives of the drug (whichever is longer) prior to the first dose of dinaciclib (Refer to Appendix 2 Drugs that interact strongly with CYP3A4).
  18. Patients requiring warfarin therapy are excluded, low molecular weight heparin is permitted.
  19. Patient has a diagnosis of immunodeficiency or is receiving ongoing immunosuppressive therapy, including systemic or enteric corticosteroids except for non-systemically absorbed treatments (such as inhaled or topical steroid therapy for asthma, chronic obstructive pulmonary disease, allergic rhinitis). Patient must be off systemic steroid or any other form of immunosuppressive therapy within 7 days prior to first dose of trial treatment.
  20. Patient is diagnosed with active autoimmune disease that has required systemic treatment in past 2 years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Note: replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment.
  21. Patient has history of interstitial lung disease or known history of, or any evidence of active, non-infectious pneumonitis.
  22. Patient has history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or prior allogeneic bone marrow transplantation or prior solid organ transplantation.
  23. Has received a live vaccine within 30 days of planned start of study therapy. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01676753

Contacts
Contact: A. Jo Chien, MD 415-885-7577 Jo.Chien@ucsf.edu
Contact: Andrei Goga, PhD 415-476-4191 andrei.goga@ucsf.edu

Locations
United States, California
UCSF Helen Diller Family Comprehensive Cancer Center Recruiting
San Francisco, California, United States, 94143
Contact: A. Jo Chien, MD    418-885-7577    Jo.Chien@ucsf.edu   
Contact: Andrei Goga, MD, PhD    415-476-4191    andrei.goga@ucsf.edu   
Principal Investigator: A. Jo Chien, MD         
Principal Investigator: Andrei Goga, MD, PhD         
Sub-Investigator: Michelle Melisko, MD         
Sub-Investigator: Mark Moasser, MD         
Sub-Investigator: Pamela N Munster, MD         
Sub-Investigator: Hope Rugo, MD         
Sub-Investigator: John Park, MD         
Sub-Investigator: Melanie Majure, MD         
Sponsors and Collaborators
Jo Chien
Merck Sharp & Dohme Corp.
Investigators
Principal Investigator: A Jo Chien, MD University of California, San Francisco
  More Information

Responsible Party: Jo Chien, UCSF Assistant Clinical Professor, University of California, San Francisco
ClinicalTrials.gov Identifier: NCT01676753     History of Changes
Other Study ID Numbers: UCSF CC# 16758
Study First Received: August 24, 2012
Last Updated: March 15, 2017

Additional relevant MeSH terms:
Breast Neoplasms
Triple Negative Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Pembrolizumab
Cyclin-Dependent Kinase Inhibitor Proteins
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on May 25, 2017